Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators.

N Engl J Med. 2006 Mar 2;354(9):911-23.

2.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
3.

[Natalizumab in the treatment of multiple sclerosis].

Horga A, Horga de la Parte JF.

Rev Neurol. 2007 Sep 1-15;45(5):293-303. Review. Spanish.

4.

[Immunosuppression with monoclonal antibodies in multiple sclerosis].

Vermersch P, Z├ęphir H.

Rev Neurol (Paris). 2007 Jun;163(6-7):682-7. Review. French.

PMID:
17607190
5.
6.

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

Rudick RA, Sandrock A.

Expert Rev Neurother. 2004 Jul;4(4):571-80. Review.

PMID:
15853576
7.
8.

Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.

Johnson KP.

Neurologist. 2007 Jul;13(4):182-7. Review.

PMID:
17622909
9.

Natalizumab for relapsing remitting multiple sclerosis.

Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007621. doi: 10.1002/14651858.CD007621.pub2. Review.

PMID:
21975773
10.

Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.

Bartt RE.

Curr Opin Neurol. 2006 Aug;19(4):341-9. Review.

PMID:
16914971
11.

Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis.

O'Connor P.

Expert Opin Biol Ther. 2007 Jan;7(1):123-36. Review.

PMID:
17150024
12.

PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.

Cohen BA, Rivera VM.

Curr Med Res Opin. 2010 Apr;26(4):827-38. doi: 10.1185/03007991003604018. Review. Erratum in: Curr Med Res Opin. 2010 Aug;26(8):1826. Dosage error in article text.

PMID:
20121658
13.

Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.

Langer-Gould A, Steinman L.

Curr Neurol Neurosci Rep. 2006 May;6(3):253-8. Review.

PMID:
16635435
14.

Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.

McCormack PL.

Drugs. 2013 Sep;73(13):1463-81. doi: 10.1007/s40265-013-0102-7. Review.

PMID:
23912625
15.

The role of natalizumab in the treatment of multiple sclerosis.

Coyle PK.

Am J Manag Care. 2010 Jun;16(6 Suppl):S164-70. Review.

16.

Progressive multifocal leukoencephalopathy and natalizumab.

Hellwig K, Gold R.

J Neurol. 2011 Nov;258(11):1920-8. doi: 10.1007/s00415-011-6116-8. Epub 2011 Jun 7. Review.

PMID:
21647730
17.

Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.

Brown JW, Coles AJ.

Drug Des Devel Ther. 2013;7:131-8. doi: 10.2147/DDDT.S32687. Epub 2013 Mar 6. Review.

18.

Clinical evaluation of natalizumab for formulary consideration.

Bivins A, Hou K, Ayesu N, Ellsworth B Jr, Montenegro S, Tu X, Boyle C, Dowling T, Shaya FT.

Expert Opin Biol Ther. 2010 Aug;10(8):1279-87. doi: 10.1517/14712598.2010.505234. Review.

PMID:
20626228
19.

Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis.

Hoy SM.

CNS Drugs. 2015 Feb;29(2):171-9. doi: 10.1007/s40263-015-0227-1. Review.

PMID:
25666445
20.

Efficacy of statins in combination with interferon therapy in multiple sclerosis: a meta-analysis.

Bhardwaj S, Coleman CI, Sobieraj DM.

Am J Health Syst Pharm. 2012 Sep 1;69(17):1494-9. doi: 10.2146/ajhp110675. Review.

PMID:
22899744
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk